Institutional investors hold a majority ownership of ALXN through the 101.07% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ALLIANCEBERNSTEIN LP Bought 641.3 Thousand shares of Alexion Pharmaceuticals I...